Your healthcare provider will check how things go as you use it
The risk was small in absolute terms, just over two in 1,000 for semaglutide users versus one in 1,000 for non-users
With GLP-1-related therapy across many of the trial-related populations, both those with and without diabetes, we see high variability in the amount of both fat mass and lean mass loss across various compounds, where the newer generation, higher-dose compounds generally have the greatest total body weight loss, but also may have higher lean mass loss as well, he said
Running them together means you are not just getting smaller
It is associated with insulin resistance, obesity, glucose intolerance and drug toxicity
formal human studies have primarily used doses up to ~300 mcg daily [6]